Identification of cytochrome P450 isoform involved in the metabolism of YM992, a novel selective serotonin re-uptake inhibitor, in human liver microsomes

References

• BACK, D. J. and TJIA, J. F., 1992, Comparative effects of the antirnycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. British Journal of Clinical Pharmacology, 32, 624–626.
   Google Scholar
• BOURRIE, M., MEUNIER, V., BERGER, Y. and FABRE, G., 1996, Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 227, 321–332.
   Google Scholar
• BOURRIE, M., MEUNIER, V., BERGER, Y. and FABRE, G., 1999, Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes. Drug Metabolism and Disposition, 27, 288–296.
   PubMed Web of Science ®Google Scholar
• CHANG, T. K. H., GONZALES, F. J. and WAXMAN, D. J., 1994, Evaluation of triacetyloleandomycin, a-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Archives of Biochemistry and Biophysics, 311, 437–442.
   Google Scholar
• GONZALES, F. J., 1992, Human cytochrome P450: problems and prospects. Trends in Pharmacological Science, 13, 346–356.
   PubMed Web of Science ®Google Scholar
• FORRESTER, L. M., HENDERSON C. J., GLANCEY, M. J., BACK, D. J., PARK, B. K., BALL, S. E., KITTERIUNGHAM, N. R., MCLAREN, A. W., MILES, J. S., SKETT, P. and WOLF, C. R., 1992, Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochemical Journal, 280, 359–368.
   Google Scholar
• GUENEGERICH, F. P., 1994, Catalytic selectivity of human cytochrome P450: relevance to drug metabolism and toxicity. Toxicology Letters, 70, 133–138.
   Google Scholar
• GUENGERICH, F. P., 1996, In vitro techniques for studying drug metabolism. journal of Pharmacokine tics and Biopharmaceutics, 24, 521–533.
   PubMedGoogle Scholar
• GUENGERICH, F. P., maLER -ENocH, D. and BLAIR, I. A., 1986, Oxidation of quinidine by human liver cytochrome P-450. Molecular Pharmacology, 30, 287–295.
   Google Scholar
• HATANAKA, K., NOIVIURA, T., FIDDAKA, K., TAKEUCHI, H., YATUSGI, S., Fum, M. and YAMAGUCHI, T., 1996, Biochemical profile of YM992, a novel selective serotonin reuptake inhibitor with 5-HT2A receptor antagonistic activity. Neuropharmacology, 35, 1621–1626.
   PubMed Web of Science ®Google Scholar
• IWATSUBO, T., SUZUKI, H., SHIMADA, N., CHB3A, K., ISHIZAKI, T., GREEN, C., TYSON, C., YOKOI, T., KAMATAKI, T. and SUGIYAMA, Y., 1997, Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. Journal of Pharmacology and Experimental Therapeutics, 282, 909–919.
   Google Scholar
• KÜPFER, A. and PREISIG, R., 1984, Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. European Journal of Clinical Pharmacology, 26, 753–759.
   PubMed Web of Science ®Google Scholar
• MURRAY, B. P., EDWARDS, R. J., MURRAY, S., SINGLETON, A. M., DAvms, D. S. and Booms, A., 1993, Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP. Carcinogenesis, 14, 585–595.
   PubMed Web of Science ®Google Scholar
• NEWTON, D. J., WANG, R. W. and Lu, A. Y. H., 1995, Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
   PubMed Web of Science ®Google Scholar
• OBACH, R. S., 1996, The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro—in vivo correlations. Drug Metabolism and Disposition, 24, 1047–1049.
   PubMed Web of Science ®Google Scholar
• OBACH, R. S., 1997, Non-specific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metabolism and Disposition, 25, 1359–1369.
   PubMed Web of Science ®Google Scholar
• PASTRAKULJIC, A., TANG, B. K., ROBERTS, E. A. and KALO W., 1997, Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochemical Phar-macology, 53, 531–538.
   PubMed Web of Science ®Google Scholar
• PEARCE, R. E., MCINTYRE, C. J., MADAN, A., SANZGIRI, U., DRAPER, A. J., BULLOCK, P. L., COOK, D. C., BURTON, L. A., LATHAM, J., NEVINS, C. and PARKINSON, A., 1996, Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Archives of Biochemistry and Biophysics, 331, 145–169.
   PubMed Web of Science ®Google Scholar
• RAHMAN, A., KORZEKWA, K. R., GROGAN, J., GONZALES, F. J. and HARRIS, J. W., 1994, Selective biotransformation of taxol to 6a-hydroxytaxol by human cytochrome P450 2C8. Cancer Research, 54, 5543–5546.
   PubMed Web of Science ®Google Scholar
• SHIMADA, T., YAMAZAKI, M., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
   PubMed Web of Science ®Google Scholar
• SPALDIN, V., MADDEN, S., ADAMS, D. A., EDWARDS, R. J., DAVIES, D. S. and PARK, B. K., 1995, Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe. Drug Metabolism and Disposition, 23, 929–935.
   PubMed Web of Science ®Google Scholar
• STEVENS, J. C., WHITE, R. B., Hsu, S. H. and MARTINET, M., 1997, Human liver CYP2B6-catalyzed hydroxylation of RP-73401. Journal of Pharmacology and Experimental Therapeutics, 282, 1389–1395.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI, H., YATSUGI, S., HATANAKA, K., NAKATO, K., HATTORI, H., SONODA, R., KOSHIYA, K. and YAMAGUCHI, T., 1997, Pharmacological studies on YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT2A receptor antagonistic activity. European Journal of Pharmacology, 329, 27–35.
   Google Scholar
• TJIA, J. F., COLBERT, J. and BACK, D. J., 1996, Theophylline metabolism in human liver microsomes: inhibition studies. Journal of Pharmacology and Experimental Therapeutics, 276, 912–917.
   PubMed Web of Science ®Google Scholar
• TSYRLOV, I. B., MIHAILENKO, V. M. and GELBOIN, H. V., 1994, Isozyme- and species-specific susceptibility of cDNA expressed CYP1A P-450s to different fiavonoids. Biochimica et Biophysica Acta, 1205, 325–335.
   PubMed Web of Science ®Google Scholar